CytomX Therapeutics, Inc.
151 Oyster Point Blvd Ste 400 South San Francisco
CA
94080-1841 United States
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results
CytomX Therapeutics (CTMX) is back in focus after reporting early Phase 1 expansion results for its EpCAM-targeting ADC, Varsetatug masetecan, in advanced colorectal cancer, alongside fresh earnings and a sizeable equity raise. See our latest analysis for CytomX Therapeutics. The latest EpCAM ADC data and the US$250.0m follow on equity raise have arrived after a sharp run, with a very large 1 year total shareholder return and a 3 year total shareholder return of 161.76%, even though the 30...
Source: Simply Wall St. Mar 21, 2026
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s
Source: Insider Monkey Mar 20, 2026
Sector Update: Health Care Stocks Slip Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and
Source: MT Newswires Mar 18, 2026
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
Source: Zacks Mar 17, 2026
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.
Source: Motley Fool Mar 16, 2026
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Source: MT Newswires Mar 16, 2026
- Adrenal Cortical Hormones
- Analgesics
- Antibiotics
- Antisera and Other Blood Fractions
- Blood-Grouping Reagents
- Diagnostic Reagents
- Immunological products, put up in measured doses
- Insulin
- Medicaments containing alkaloids or derivatives
- Medicaments containing antibiotics
- Medicaments containing hormones
- Medicaments containing penicillins or derivatives
- Medicaments containing vitamins or provitamins
- Medicinal Capsules
- Ophthalmic Medicines
- Sterile surgical catgut, similar ster ile suture materials
- Vaccines for Human Medicine
- Wadding, gauze, bandages and similar articles
- Analgesics
- Antibiotics
- Antihistamines
- Antimalarial Drugs
- Antineoplastic and immunosuppressive medicaments
- Antivirals
- Cancer Drugs
- Erythromycin and its derivatives
- Insulin
- Insulin and its salts
- Medicaments containing hormones or steroids
- Ophthalmic Solutions
- Paracetamol (acetaminophen)
- Penicillin and its derivatives
- Steroidal Hormones
- Streptomycins and their derivatives
- Tetracyclines and their derivatives
- Vaccines for Human Medicine
- Vitamins and their derivatives
IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.
All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.